Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MITF | O75030 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.45 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5561079 | 1.00 | ALDH1A1 (0.50) | ALDH1A1MITFHTTRAB9AGFER | |
| SCHEMBL2911573 | 1.00 | ALDH1A1 (0.50) | ALDH1A1MITFHTTRAB9AGFER | |
| SCHEMBL3051447 | 0.98 | ALDH1A1 (0.49) | ALDH1A1MITFHTTRAB9AGFER | |
| SCHEMBL15767970 | 0.98 | ALDH1A1 (0.49) | ALDH1A1MITFHTTRAB9AGFER | |
| Hydrochloric Acid SCHEMBL6009377 | 0.98 | ALDH1A1 (0.53) | ALDH1A1MITFHTTRAB9AGFER | |
| Hydrochloric Acid SCHEMBL12487350 | 0.98 | ALDH1A1 (0.53) | ALDH1A1MITFHTTRAB9AGFER | |
| Hydrochloric Acid SCHEMBL20238067 | 0.98 | ALDH1A1 (0.53) | ALDH1A1MITFHTTRAB9AGFER | |
| Hydrochloric Acid SCHEMBL4347694 | 0.98 | ALDH1A1 (0.53) | ALDH1A1MITFHTTRAB9AGFER | |
| SCHEMBL4821437 | 0.98 | ALDH1A1 (0.49) | ALDH1A1MITFHTTRAB9AGFER | |
| Hydrochloric Acid SCHEMBL4357625 | 0.98 | ALDH1A1 (0.53) | ALDH1A1MITFHTTRAB9AGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9303027-B2 | Kappa opioid receptor agonists | DR. REDDY'S LABORATORIES LTD. (IN) | 2016-04-05 | — | — | US | claimed |
| US-20130303525-A1 | KAPPA OPIOID RECEPTOR AGONISTS | DR. REDDY'S LABORATORIES, INC. (US) | 2013-11-14 | — | — | US | claimed |
| WO-2012012410-A2 | KAPPA OPIOID RECEPTOR AGONISTS | DR. REDDY'S LABORATORIES LTD. (IN) | 2012-01-26 | — | — | WO | claimed |
| US-5472961-A | Acetamides | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1995-12-05 | — | — | US | claimed |
| EP-3551626-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2019-10-16 | — | — | EP | disclosed |
| EP-2966054-B1 | METHOD OF PRODUCING OPTICALLY-ACTIVE ALDEHYDE | TAKASAGO PERFUMERY CO LTD (JP) | 2019-01-02 | — | — | EP | disclosed |
| EP-2822928-B1 | SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS | Dr Reddys Laboratories Ltd (IN) | 2018-11-14 | — | — | EP | disclosed |
| US-10029969-B2 | Method of producing optically-active aldehyde | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2018-07-24 | — | — | US | disclosed |
| WO-2018106284-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2018-06-14 | — | — | WO | disclosed |
| WO-2018106284-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2018-06-14 | — | — | WO | disclosed |
| CN-104271552-B | Substituted heterocyclic acetamides as KAPPA Opioid Receptor (KOR) agonists | 雷迪博士实验室有限公司 | 2017-08-08 | — | — | CN | disclosed |
| US-20170001998-A1 | SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS | DR. REDDY'S LABORATORIES, LTD. (IN) | 2017-01-05 | — | — | US | disclosed |
| CN-1041087-C | Arylacetamides | MERCK PATENT AG (DE) | 1998-12-09 | — | — | CN | disclosed |
| EP-0569802-B1 | Arylacetamides | MERCK PATENT GMBH (DE) | 1998-07-15 | — | — | EP | disclosed |
| US-5532266-A | Acrylacetamides | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1996-07-02 | — | — | US | disclosed |
| CN-1121072-A | Acetamides | MERCK PATENG GES MIT BESCHRANK (DE) | 1996-04-24 | — | — | CN | disclosed |
| US-5472961-A | Acetamides | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1995-12-05 | — | — | US | disclosed |
| EP-0670318-A2 | Acetamides with analgesic and neuroprotective activity | MERCK PATENT GmbH (DE) | 1995-09-06 | — | — | EP | disclosed |
| CN-1079219-A | Arylacetamide | MERCK PATENT GMBH (DE) | 1993-12-08 | — | — | CN | disclosed |
| EP-0569802-A1 | Arylacetamides | MERCK PATENT GmbH (DE) | 1993-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10029969-B2 | Method of producing optically-active aldehyde | ALDH3A1, ALDH1A2, ADH1A | ALDH1A1 6/4885MITF 1982/4885HTT 4684/4885 |
| US-20170001998-A1 | SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS | OPRK1, OPRL1, OPRD1 | ALDH1A1 786/4885MITF 4025/4885HTT 2847/4885 |
| US-20130303525-A1 | KAPPA OPIOID RECEPTOR AGONISTS | OPRK1, OPRL1, OPRD1 | ALDH1A1 1649/4885MITF 3668/4885HTT 3363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.